Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 22Bevacizumab 10Radiotherapy 5Magnetic Resonance Spectroscopy 5Irinotecan 5Carmustine 4fluorodopa F 18 3Topotecan 3Surgical Procedures, Operative 3Standard of Care 3Radiosurgery 3Magnetic Resonance Imaging 3Congresses as Topic 3Carboplatin 3Aminolevulinic Acid 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3ribociclib 2poly ICLC 2fluoromisonidazole 2carmustine, poliferprosan 20 drug combination 2cabozantinib 2Vorinostat 2TIC10 compound 2Re-Irradiation 2Radiotherapy, Intensity-Modulated 2Panobinostat 2O(6)-benzylguanine 2Melphalan 2Lomustine 2Lacosamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Glioma × regadenoson × Clear all
NCT03971734 2023-10-06

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
7 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡